Pulmonary Fibrosis

Latest News

Nerandomilast is an investigational oral, preferential inhibitor of phosphodiesterase 4B that has shown promise in IPF and PPF. | Image credit: Елена Бутусова - stock.adobe.com
Nerandomilast Improves Lung Function in Progressive Pulmonary Fibrosis: FIBRONEER-ILD

February 13th 2025

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.

IPF Top 5 of 2024 | Image Credit: Venngage
Top 5 Most-Read IPF Content of 2024

December 23rd 2024

 Man yawning at work | Image Credit: LIGHTFIELD STUDIOS - stock.adobe.com
Patients With ILD Face Higher Burden of Fatigue, Excessive Daytime Sleepiness

December 13th 2024

Highlights from ERS Congress 2024
ICYMI: Highlights From ERS Congress 2024

December 6th 2024

Breaking Ground in IPF Care: 2024 Year-in-Review

Discover the latest advancements in idiopathic pulmonary fibrosis (IPF) care. Our 2024 Year-in-Review: Idiopathic Pulmonary Fibrosis highlights breakthroughs, clinical trial insights, and emerging therapies shaping the future of IPF management.

Discover the latest advancements in idiopathic pulmonary fibrosis (IPF) care. Our 2024 Year-in-Review: Idiopathic Pulmonary Fibrosis highlights breakthroughs, clinical trial insights, and emerging therapies shaping the future of IPF management.
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo